Technical Study: ACADIA Pharma Inc., Medivation Inc., Sarepta Therapeutics Inc., and Cell Therapeutics Inc. PR Newswire LONDON, August 19, 2013 LONDON, August 19, 2013 /PRNewswire/ -- Editor Note: For more information about this release, please scroll to bottom. The US equity market ended on a lower note on Friday, August 16, 2013. The Dow Jones Industrial Average closed at 15,081.47, down 0.20%, the S&P 500 closed at 1,655.83, down 0.33%, and the NASDAQ composite finished at 3,602.78, down 0.09%. However, shares in biotechnology companies closed on a higher note. The major movers in the sector included ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), Medivation Inc. (NASDAQ: MDVN), Sarepta Therapeutics Inc. (NASDAQ: SRPT), and Cell Therapeutics Inc. (NASDAQ: CTIC). AAAResearchReports.com free coverage on ACAD, MDVN, SRPT, and CTIC is available upon registration at: http://www.aaaresearchreports.com/register/ ACADIA Pharmaceuticals Inc.'s shares ended 0.41% higher on Friday, reversing some of their recent losses. The company's stock oscillated between $19.27 and $20.25 before closing the day at $19.70. A total of 1.49 million shares were traded, which is below the daily average volume of 3.08 million. The company's shares have lost 2.09% in the previous three trading sessions and in the last one month. Despite recent losses, ACADIA Pharmaceuticals Inc.'s stock has gained 48.46% in the last three months, outperforming the S&P 500 which has fallen 0.70% during the same period. Moreover, the stock is trading above its 50-day and 200-day moving averages. Download free technical research on ACAD by signing up at: http://www.AAAResearchReports.com/ACAD081913.pdf Shares in Medivation Inc. edged higher on Friday, even as the broader market ended on a lower note. The company's stock ended the day at $55.89, up 0.25%, after oscillating between $54.94 and $56.79. A total of 1.62 million shares were traded, which is above the daily average volume of 1.04 million. Medivation Inc.'s stock has gained 17.59% in the last three months, compared to a decline of 0.70% in the S&P 500 during the same period. Further, the stock is trading above its 50-day and 200-day moving averages. Register now and get access to free analysis on MDVN at: http://www.AAAResearchReports.com/MDVN081913.pdf Shares in Sarepta Therapeutics Inc. rose sharply on Friday, reversing losses from the previous trading session. The company's shares fluctuated between $32.45 and $34.71 before ending the day 3.25% higher at $33.08. A total of 3.07 million shares were traded, which is significantly above the daily average volume of 1.66 million. The company's shares have gained 4.88% in the last three trading sessions, outperforming the S&P 500 which has fallen 2.26% during the same period. Additionally, the stock is trading above its 200-day moving average. Sign up and read our complimentary report on SRPT at: http://www.AAAResearchReports.com/SRPT081913.pdf Shares in Cell Therapeutics Inc. ended higher on Friday, even as the broader indices declined. The company's shares gained 0.95% ending at $1.06 after fluctuating between $1.06 and $1.09. A total of 0.49 million shares were traded, which is below the daily average volume of 1.16 million. Cell Therapeutics Inc.'s shares have fallen 0.93% in the previous three trading sessions, outperforming the S&P 500 which has fallen 2.26% during the same period. The free report on CTIC can be downloaded by signing up now at: http://www.AAAResearchReports.com/CTIC081913.pdf EDITOR NOTES: 1.This is not company news. We are an independent source and our views do not reflect the companies mentioned. 2.Information in this release is fact checked and produced on a best efforts basis and reviewed by a CFA ® charterholder. However, we are only human and are prone to making mistakes. If you notice any errors or omissions, please notify us below. 3.This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public. 4.If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com. 5.For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com. 6.Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration. COMPLIANCE PROCEDURE Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider has, through Chartered Financial Analysts, only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be. NOT FINANCIAL ADVICE Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein. NO WARRANTY OR LIABILITY ASSUMED Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. SOURCE AAA Research Reports Contact: Contact Name: Peter F. Jones, Phone #: +1(646)396-9126, Email ID: email@example.com
Technical Study: ACADIA Pharma Inc., Medivation Inc., Sarepta Therapeutics Inc., and Cell Therapeutics Inc.